The company has developed the first cellular therapy derived from primary cells to repair a diseased organ. The team published this breakthrough in the Science journal, which was echoed by The Telegraph and The Times.
Biliduct repairs organs by combining human cells with biologically- or chemically-derived scaffolds. To address this challenge Bilitech has developed a technology for the generation of artificial bile ducts in the laboratory. This technology has been successful in generating miniature bile ducts which were used to successfully replace the bile duct of mice.
Bilitech's overall aim is to advance this product from its current miniature form to a viable clinical therapy for humans. Through the discussions of pitch deck Value Proposition and market size was inevitably discussed and the size of the Biliduct market proved to be small for the standards of VC requirements. However, it emerged that the cell lines used in the process of generating Biliduct can be used as a lone standing product used in drug discovery and testing process with a far more lucrative market.
Innovate UK EDGE have supported client with investment readiness, helping to produce their pitch deck and business plan as well as looking at strategy (pivot from Biliduct to Bilicell) and IP.
Innovate UK EDGE have assisted with strategy to pivot from primary product to secondary product with higher potential for market growth and enhancement of investment readiness in preparation for funding round with CIS and other investors. Expected outcomes include raising £500k investment in the next year.
